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To investigate whether eosinophils are stimulated in vtvo
or have acquired an increased susceptibility to stimuli
from the coagulation cascade, the release of eosinophil
proteins was compared for three groups of donors with
different levels of serum IgE. (1) with atopic dermatitis
(s-IgE> 5000 IU/ml, n= 11); (2) with inhalant allergy
(200 < s-IgE < 2 000 IU/ml, n 10); and (3) non-allergic (s-
IgE < 100 IU/ml, n 10). The levels of eosinophil cationic
protein and eosinophil protein X (ECP, EPX) were deter-
mined in serum (clotting time 2.0 h) and plasma. Serum
and plasma ECP in normal donors demonstrated large
intra-personal variations (C.V. 50-80%), but serum-ECP
(mean 8.1ng/ml) was clearly distinguishable from
plasma ECP (mean 1.0 ng/ml) by a factor of 8 (range:
5.6-11.6). The ECP released during clottingwas markedly
increased in the atopic dermatitis group (serum:plasma
ratio 13.5, p < 0.003) compared with the other groups
(6.7 and 5.6). EPX, having a higher plasma level, demon-
strated a less pronounced release (serum: plasma ratios
2.0, 1.7 and 1.4), with no statistical difference between
donor groups. Considering all donors together the levels
ofECP and EPX in plasma and in serum were correlated
to the number of eosinophils (coefficients of correlation
0.54-0.58, p < 0.002).
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Introduction
Increased levels of plasma IgE and accumulation of
eosinophils in blood and inflamed tissues are consid-
ered to be two important immunological features in
allergic disease. 1," In animal models the interleukins
4 and 5 (IL-4 and IL-5) have been demonstrated to
induce IgE synthesis, eosinophilia and eosinophil
activation,>5 and these properties have been con-
firmed in human in vitro studies. Thus, a link
seems to exist between the high levels of serum IgE
and eosinophil activation. To investigate whether
patients with atopic dermatitis (severely increased
IgE), inhalant allergy (moderately increased IgE) or
normal individuals have different in vivo stimulation
of eosinophils or have an increased susceptibility to
stimuli, the mediator release from eosinophils was
investigated. Moreover, this mediator release was
compared with the donors’ potential for in vitro
productionof IgE, which had previously been deter-
mined.
Many preformed and de novo synthesized media-
tors may be released from the eosinophil and differ-
ent experimental models have been suggested for
monitoring mediator release.-1 The present ap-
proach was based on the fact that coagulation of
blood induces a release of both eosinophil cationic
protein (ECP) and eosinophil protein EPX (EPX)
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from the cells.1 This model was chosen because
it was speculated that this weak stimulus may
only induce degranulation of in vivo activated
eosinophils.
Materials and Methods
Allergic and non-allergic donors: For the longitudi-
nal study of the biological variation of the levels of
ECP and EPX in serum and plasma six non-allergic,
male donors were used.
Three groups of donors were admitted to the
second part of the study. Group 1 showed atopic
dermatitis with hyper-serum-IgE, and consisted of
eleven individuals with serum IgE > 5 000 KIU/1. All
patients in this group displayed atopic dermatitis
according to the criteria of Hanifin and Rajka."
Group 2 consisted of ten allergic patients each with
total IgE in the range 200-2 000 KIU/1, and inhalant
allergy to pollen, house dust mites or animal dander.
The diagnosis was established by case history, posi-
tive skin prick test and presence of allergen specific
IgE. Group 3 consisted of ten non-allergic subjects,
each with total IgE < 100KIU/ml and no history of
allergy.
The age profiles were similar in the three groups
(35.8 + 11.0, 39.0 + 11.3 and 35.2 + 5.6 years) as were
the distributions between the two sexes: F/M, 7/4,
Mediators of Inflammation. Vol 3. 1994 223L. K. Poulsen, C. M. Reimert and C. Bindslev-Jensen
3/7 and 6/4. Total serum IgE in the three groups
were: 12000 _+ 9200, 485 +_ 416, and 32 _+ 30 KIU/1.
Apart from the eosinophil counts (0.51 109/1,
0.18 x 109/1 and 0.13 x 109/1) no abnormal or varying
haematological parameters were observed.
None of the donors had received systemic
glucocorticoid treatment or cytostatic treatment 8
weeks prior to the studies, and no patients were
undergoing allergen specific immunotherapy.
Blood sampling: Plasma and serum for ECP and EPX
determinations were prepared from blood samples
drawn in Vacutainers (Labco Inc., Bucks, UK) with
EDTA or without anticoagulant, and allowed to clot
for exactly 2 h at room temperature, which averaged
at 21C (range 20-23C) during the study period.
Counting of eosinophils was performed automati-
cally using a Coulter counter.
ELISAforECP and EPX: Serum and plasma levels of
ECP and EPX were determined by ELISA methods
described in detail elsewhere. 13,14 Briefly, both assays
are sandwich type employing specific rabbit antibod-
ies to ECP/EPX and the biotin-avidin amplification
system. ECP and EPX are determined in the ranges
of 15-1000 and 60-2 000 pg/ml, respectively. Before
measurement the samples were diluted in PBS (pH
7.4) containing 0.1% Tween 20, 0.1% CTAB (N-cetyl-
N,N,N-trimethyl ammonium bromide), 20 mM EDTA,
0.2% human serum albumin.
In vitro IgE synthesis: The spontaneous and
interleukin 4 (IL-4) induced IgE synthesis of periph-
eral blood mononuclear cells (PBMC) have previ-
ously been determined (Poulsen et al., in prepara-
tion). Briefly, cells were isolated from heparinized
blood using LymphoPrep
TM (Nycomed, Oslo, Nor-
way) and subsequently washed three times in me-
dium. For in vitro synthesis of IgE, cells were grown
in 96-well plates (200 t-tl at 2 x 106/ml) in the medium
described by Ysse115 at 37C, in a humidified atmos-
phere containing 5% CO,.. Cells and medium were
transferred to new wells at day 2, and the
supernatants were harvested at day 11. Control cul-
tures were acid extracted at day 0 as described, 16 and
IgE was determined by an immunoradiometric assay
(sensitivity 50 pg/ml).
17
Statistics: The Mann-Whitney test for unpaired and
the Wilcoxon test for paired observations were ap-
plied for testing differences between groups. Coeffi-
cient of correlation was calculated as Spearman’s rho.
Results
Day-to-day variations in plasma and serum ECP in
non-allergic donors: The levels of ECP and EPX in
serum were stro.ngly dependent on the time and
Table 1. Variation of ECP when determined in serum (coagulation
time, 2 h, temp, 21C) and plasma of eight blood samples drawn
from six non-allergic donors during a period of 11 weeks
Serum ECP (ng/ml)
Donor 2 3 4 5 6 Mean
Mean 9.79 4.25 9.58 14.14 5.18 5.46 8.07
S.D. 10.27 2.00 14.77 11.21 1.87 2.48
C.V.(%) 104.9 47.1 150.0 79.3 36.1 45.4 77.1
Plasma ECP (ng/ml)
Donor 2 3 4 5 6 Mean
Mean 1.49 0.63 1.07 1.22 0.92 0.89 1.04
S.D. 1.14 0.24 0.58 0.60 0.35 0.36
C.V.(%) 76.5 38.1 54.2 49.2 38.0 40.4 49.4
Blood was drawn (cf. Materials and Methods) each week in weeks
No. 1, 2, 3, 4, 5, 6, 7 and 11. No systematic changes were seen
between the individual weeks. S.D. standard deviation.
C.V. coefficient of variation.
temperature during clotting of the blood sample. To
investigate the biological variations when these two
factors were carefully controlled, an experiment was
performed in which the levels of serum and plasma
ECP were determined in blood sampled from non-
allergic donors during a period of 11 weeks. Table 1
illustrates the variation of ECP when determined in
serum (coagulation time, 2.0 h) and EDTA-plasma of
eight blood samples drawn from six non-allergic
donors with intervals of 1 week or more. The mean
serum level for this group was 8.07 ng/ml compared
with 1.04 ng/ml for plasma. The coefficients of vari-
ation were larger for serum than for plasma values
with averages of 77% and 49% respectively. In spite
of these variations there was a clearly increased level
of ECP in serum compared with plasma indicating an
in vitro release of eosinophil proteins during coagu-
lation of blood. Statistical analysis of the correlations
between the number of eosinophils and the serum or
plasma levels of ECP for each of the six donors did
not reveal any significant correlation, indicating that
intra-personal fluctuations in ECP levels were caused
by other factors than the absolute number of
eosinophils.
ECP and EPX in serum andplasma of non-allergic
and atopic donors: Fig. 1A shows the levels of ECP
in plasma and serum from the three donor groups. As
for the normal donors a marked higher level of ECP
was seen in serum compared with plasma. This was
the case for all three groups, but most pronounced
in the atopic dermatitis group, which had an in-
creased (p < 0.003) median serum-to-plasma ratio of
13.5 compared with 6.7 and 5.6 for the allergic and
the non-allergic groups. The levels of EPX in serum
and plasma generally demonstrated the same
features as seen for ECP (Fig. 1B). The plasma level
for EPX, however, was more than ten times that of
ECP, making the in vitro release of EPX from the
eosinophils into the serum less pronounced. Thus
the median EPX serum-to-plasma ratios of the three
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plasma vs. serum plasma vs. serum plasma vs. serum groups were only 2.0, 1.7 and 1.4 respectively (not
statistically different).
When considering all donors together, significant
correlations were found between eosinophil number
vs. serum and plasma levels of both ECP (r= 0.58
and r= 0.54, p< 0.0001 and p< 0.002) and EPX
(r= 0.55 and r= 0.58, p < 0.002 and p < 0.0001). No
such correlations were found within the three
groups.
To investigate whether the higher serum-to-plasma
ratio in the atopic dermatitis group reflected a higher
state of activation (analogous to the ’releasability’
concept for basophilsTM) or merely a higher number
of eosinophils, the amounts of released protein were
calculated on a per cell basis. Fig. 2 illustrates the
amounts of released ECP and EPX (i.e., the serum
0 value minus the plasma value) per eosinophil cell.
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There was a low but significant correlation (r= 0.56,
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| O< 0.001) between the amount of the two proteins,
10
| . ;tnd no differences were found among the three
:lonor groups in respect of the distribution of ECP vs.
EPX. However, the eosinophils generally seemed to
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release slightly more EPX than ECP. Moreover, the so
serum plasma verall levels of released ECP and EPX varied more
Atopic dermatitis Allergic Non-allergic etween individual donors than between groups.
Correlation between IgE synthesis and release of
eosinophilic proteins: The atopic dermatitis group B 12o- demonstrated high spontaneous and IL-4 induced
plasma vs. serum plasma vs. serum plasma vs. serum IgE synthesis (Poulsen et al., in preparation) and a
100 .. higher number of eosinophils, including an in-
creased release of ECP to serum during clotting of
blood. To see if this correlation could be extended
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FIG. 1. Serum and plasma levels of ECP (A) and EPX (B). Blood samples
were allowed to incubate for 2 h at 21C and serum or plasma was har-
vested. The lower panel gives the ratios between the serum and the plasma
levels for the individual donors.
FIG. 2. The coagulation induced release of ECP and EPX per eosinophil
cell. The cellular release was calculated as the difference between serum
and plasma levels divided by the eosinophil cell number. Samples were
incubated for 2 h at 21C. @, atopic dermatitis patients; ’, allergic patients;
I, non-allergic patients.
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Table 2. Correlation between the spontaneous and IL-4 induced
IgE synthesis and eosinophil count, ECP level in serum, and the
ECP serum:plasma ratio
Spontaneous IgE IL-4 induced IgE
synthesis synthesis
r p r p
Eosinophil count 0.52 0.0076 0.46 0.0085
ECP in serum 0.53 0.0060 0.43 0.0168
ECP serum:plasma ratio 0.51 0.0099 0.40 0.0260
Spontaneous IgE synthesis was calculated as IgE in culture
supernatants minus IgE in cultures at day O. IL-4 induced IgE
synthesis was calculated as the difference between
supernatants + IL-4.
to the entire material, i.e. the allergic and the non-
allergic groups, the correlation was determined be-
tween the spontaneous and IL-4 induced synthesis
on the one hand and the eosinophil parameters on
the other. For EPX no correlation was found,
whereas significant correlations were found between
the spontaneous and the IL-4 induced IgE synthesis
and eosinophil count, serum ECP and, consequently,
the ECP serum:plasma ratio (Table 2). The correla-
tion between ECP release and IgE synthesis was not
superior to the IgE-synthesis-eosinophil count corre-
lations, indicating no direct links between eosinophil
’releasability’ and potential for IgE synthesis. More-
over, when ECP release was calculated on a ’per cell
basis’ as described above, no significant correlations
were found for either spontaneous or IL-4 induced
IgE synthesis. Generally, the eosinophil count, serum
levels and serum:plasma ratios correlated better to
the spontaneous synthesis, compared with the syn-
thesis induced by IL-4.
Discussion
Several studies have shown the strong correlation
between eosinophilia and IgE related diseases such
as allergy, atopic dermatitis19 and parasitosis,
2 but
the exact mechanisms by which the eosinophils are
recruited and activated are still enigmatic. As Th2
type cytokines like IL-5 and granulocyte macrophage
colony stimulating factor (GM-CSF) have been in-
criminated in the degranulation, it was speculated
that eosinophil activation would be present in do-
nors featuring an active IgE synthesis.
It has been suggested that serum levels of
eosinophilic proteins may be used as markers of the
number of eosinophils in peripheral blood. How-
ever, we have previously demonstrated a large dis-
crepancy between serum and plasma levels, and a
strong time and temperature dependent release of
ECP and EPX from eosinophils when a blood sample
is allowed to coagulate.
1. This indicated that the
eosinophils are induced to release the proteins by
the coagulation process. Moreover, these data sug-
gested that measurements of serum ECP should be
carried out very cautiously using standardized proce-
dures. To test the day-to-day variations, a longitudi-
nal study of non-allergic donors was performed, and
as illustrated in Table 1, variations of 50-80%
occurred between different days. The ECP levels
in plasma could, however, be clearly discriminated
from the corresponding serum values that were in-
creased by a factor of 8. Accordingly, the second part
of the study was carried out, in which the coagula-
tion induced release of ECP and EPX was studied in
donors of varying atopic status.
Regarding the ECP release a marked difference was
observed between the atopic dermatitis group and
the two other groups (Fig. 1). It cannot be con-
cluded, however, that this difference stems from
different levels of activation. More likely the differ-
ence reflects the fact that the release of ECP during
the clotting of blood is related only to the number of
eosinophils. This is emphasized in Fig. 2, in which no
special release pattern of ECP or EPX on a per cell
basis is seen in any of the three groups. As we have
not determined the number of normodense vs.
hypodense eosinophils in the blood of the patients,
it is also possible that the blood eosinophils have not
been activated and that activated eosinophils are
located exclusively in the target organ of the inflam-
matory process.
From Table 2 it is seen that correlations exist
between the serum level of ECP and the
serum:plasma ratio of ECP on the one hand and the
spontaneous and IL-4 induced IgE synthesis on the
other. The two eosinophil parameters do not, how-
ever, correlate better than the eosinophil count, sug-
gesting that the atopic status affects only the
eosinophilopoiesis and not the activation degree of
the eosinophils in the peripheral blood.
Several experimental models have been suggested
for monitoring mediator release of the eosinophil
granulocyte.
8-1 It should be emphasized that our
approach, i.e. mediator release caused by coagula-
tion of blood, induces a substantially lower release
than the one induced by complement- or IgA/IgG-
dependent mechanisms, which can induce even nor-
modense, i.e. non-activated eosinophils, to degran-
ulate. The coagulation induced degranulation was
chosen, however, because it was speculated that this
weak stimulus may only induce degranulation of
in vivo activated eosinophils. Although the exact
mechanism by which the cells degranulate is not
known, it seems to be a calcium-dependent secretion
because heparinized plasma contains higher
amounts of ECP and EPX.
In conclusion we have found a correlation be-
tween the number of eosinophils and the release of
ECP and EPX to serum during a specified period.
Provided that the technical difficulties of standardiz-
ing drawing and coagulation of blood are solved, the
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release of eosinophilic proteins probably reflects a
combination of the number of the activation state of
the eosinophils. The group of inhalant allergic do-
nors fell between the atopic dermatitis and the non-
allergic individuals in both eosinophil numbers and
protein levels, but no significant differences to the
latter group could be demonstrated. During the
eosinophilopoiesis the cell spends a relatively brief
period in circulation before it is recruited to inflam-
matory foci. Thus it is possible that higher numbers
of activated eosinophils and hence a larger coagula-
tion induced release can be found in patients in a
more active state of their disease.
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